Free Trial
→ SpaceX IPO hides a much bigger story (From Weiss Ratings) (Ad)tc pixel
NASDAQ:BNTC

Benitec Biopharma Q3 2026 Earnings Report

Benitec Biopharma logo
$12.49 +0.29 (+2.37%)
As of 12:24 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Benitec Biopharma EPS Results

Actual EPS
N/A
Consensus EPS
-$0.27
Beat/Miss
N/A
One Year Ago EPS
N/A

Benitec Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
$4.55 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Benitec Biopharma Announcement Details

Quarter
Q3 2026
Date
5/13/2026
Time
Before Market Opens
Conference Call Date
Thursday, May 14, 2026
Conference Call Time
9:30AM ET

Conference Call Resources

Benitec Biopharma Earnings Headlines

Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the ...
April 29, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/benitec-biopharma-announces-oral-presentation-of-interim-phase-1b-2a-clinical-study-results-for-high-dose-bb-301-and-continued-durable-improvements-for-low-dose-bb-301-at-the-2026-american-society-1036071304
Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting
April 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/28/3282427/0/en/benitec-biopharma-announces-oral-presentation-of-interim-phase-1b-2a-clinical-study-results-for-high-dose-bb-301-and-continued-durable-improvements-for-low-dose-bb-301-at-the-2026-.html
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
May 6 at 1:00 AM  |  Profits Run (Ad)
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued ...
March 10, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/benitec-biopharma-to-host-industry-forum-breakfast-event-at-the-2026-muscular-dystrophy-association-clinical-and-scientific-conference-on-march-10-2026-highlighting-continued-progress-for-bb-301-1035913741
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)
March 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/10/3252609/0/en/benitec-biopharma-to-host-industry-forum-breakfast-event-at-the-2026-muscular-dystrophy-association-clinical-and-scientific-conference-on-march-10-2026-highlighting-continued-progr.html
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular ...
March 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/benitec-biopharma-announces-positive-interim-110000867.html
See More Benitec Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Benitec Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Benitec Biopharma and other key companies, straight to your email.

About Benitec Biopharma

Benitec Biopharma (NASDAQ:BNTC) Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions. The hepatitis B program is advancing through preclinical studies to demonstrate potent and durable suppression of viral replication. In ocular disease, the company is exploring local delivery approaches to address wet age-related macular degeneration and other retinal disorders with RNAi-based constructs.

Founded and headquartered in Australia, Benitec maintains research operations in both Melbourne and San Diego, California. Its international footprint supports collaboration with academic centers and contract development organizations to accelerate preclinical evaluation and future clinical trials. The company holds a portfolio of intellectual property covering its ddRNAi technology and related gene-silencing applications.

Led by a management team with experience in gene therapy, molecular biology and drug development, Benitec Biopharma is focused on translating its platform into clinical-stage assets. The company continues to explore partnerships and licensing opportunities to broaden the scope of its gene-silencing pipeline and advance novel treatments toward regulatory approval.

View Benitec Biopharma Profile
Earnings Tools